CRISPR Therapeutics...The next level....!

As of December 31, 2016 and 2015, we had cash of approximately $315.5 million and $156.0 million, respectively. We expect that our existing cash, including the net proceeds from our IPO and the concurrent private placement, together with anticipated research support under our joint venture with Bayer Healthcare and collaboration agreement with Vertex, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 24 months.

und hier noch die Forschungstätte.....

Operating Leases
In August, 2016, Casebia entered into an agreement with Pfizer, Inc. to sublease 32,688 square feet of office and laboratory space in Cambridge, MA. The sublease commenced in October, 2016, expires in March, 2024 and includes a tenant improvement allowance of $5.4 million, of which Casebia has recorded $4.1 million as leasehold improvements and $1.3 million as tenant improvement allowance receivable at December 31, 2016. Casebia has the option to extend the term of the sublease by five years.

Security CRSP / CRISPR Therapeutics AG (H17182108)
Institutional Owners         65
Institutional Shares        16,542,728
Outstanding Shares        40,088,718 (as of 2017-09-30)
Institutional Value    $ 181,754,000 USD

CRISPR Therapeutics AG (NASDAQ:CRSP) has 65 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 16,542,728 shares. Largest shareholders include Celgene Corp /de/, NEA Management Company, LLC, Versant Venture Capital IV, L.P., Abingworth LLP, Clough Capital Partners L P, Franklin Resources Inc, Global Thematic Partners, LLC, New Leaf Venture Partners, L.L.C., Orbimed Advisors Llc, and Granahan Investment Management Inc/ma.

fintel.io/so/us/crsp

Disruptor Alert: These 5 Companies Are Changing Healthcare


.. " Genbearbeitung: CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics

Das Bearbeiten von Genen beinhaltet die Insertion, Deletion oder den Austausch von DNA in einer Zelle oder einem Organismus. Während es mehrere Möglichkeiten gibt, Gene zu bearbeiten, ist die derzeit aufregendste Technik geclusterte, regelmäßig interpolierte kurze palindromische Wiederholungen oder CRISPR, ein Ansatz, bei dem ein in Bakterien vorkommendes Enzym die DNA verändert.

Drei kleine Unternehmen stehen bei der Verwendung von CRISPR an vorderster Front: CRISPR Therapeutics, Editas Medicine und Intellia Therapeutics. Jedes dieser Unternehmen verwendet CRISPR-Gen-Editing, um auf mehrere Krankheiten abzuzielen. Einige dieser Krankheiten sind, wie Sie vielleicht erwarten, durch genetische Mutationen verursacht. Zum Beispiel arbeiten CRISPR Therapeutics und Editas an Therapien zur Behandlung von Mukoviszidose und Duchenne-Muskeldystrophie. Alle drei Unternehmen erforschen jedoch auch die Verwendung von Gen-Editing auf den körpereigenen Immunzellen, um Krebs zu bekämpfen, der nicht mit genetischen Mutationen verbunden ist.

Die Möglichkeiten für die CRISPR-Genbearbeitung sind enorm. Manche sehen einen Tag vor, an dem viele genetische Krankheiten geheilt oder gar verhindert werden können. Andere sehen das Potenzial für noch effektivere Krebsbehandlungen mit genetisch veränderten Zellen. Unabhängig davon, ob diese Träume Wirklichkeit werden, könnte die Arbeit, die CRISPR Therapeutics, Editas Medicine und Intellia Therapeutics heute leisten, die Art und Weise, wie Krankheiten in Zukunft behandelt werden, stark verändern. "

G übersetzt.
Quelle :
www.nasdaq.com/article/...ies-are-changing-healthcare-cm876834

gizmodo.com/in-2018-we-will-crispr-human-beings-1821540150


"But if 2017 was the year that the potential of CRISPR began to come into focus, 2018 may be the year that potential begins to be realized.

Next year, the first human trials of CRISPR-based treatments in the U.S. and Europe are slated to begin.

This month, biotech firm CRISPR Therapeutics became the first to submit a clinical trial application to European regulators. Tests are set to begin next year for its therapy that combines CRISPR gene editing and stem cell therapy to treat the blood disorder beta thalassemia. CEO Samarth Kulkarni told Gizmodo that the company also plans to file an application to conduct a clinical trial using a similar therapy to treat sickle cell disease in the first half of 2018. “In 2018, the first human is going to get dosed with CRISPR in the clinic,” Kulkarni told Gizmodo. “And we’re going to be the first ones to do it.”

ir.crisprtx.com/...54376&p=irol-newsArticle&ID=2325050

ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 5,000,000 of its common shares at a public offering price of $22.75 per share, before underwriting discounts. In addition, CRISPR Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 750,000 of its common shares. CRISPR Therapeutics anticipates the gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, to be approximately $113.75 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about January 9, 2018, subject to customary closing conditions

seekingalpha.com/article/...ars-moo-stock-market-outlook-2018

.."Recently, we published a Biotech Bonanza: Market Outlook for 2018 article which outlines the various reasons that suggest the sector can finally make an all-time high in 2018.

Just a few of the promising smallcap and biotech names include Alnylam Pharmaceuticals (ALNY), Vertex Pharmaceuticals (VRTX), Sage Therapeutics (SAGE), Nektar Therapeutics (NKTR), Immunomedics (IMMU), Xunlei Limited (XNET), CVR Refining (CVRR), Spectrum Pharmaceuticals (SPPI), AnaptysBio (ANAB), Century Aluminum (CENX), Insmed (INSM), GDS Hldgs (GDS), Foundation Medicine (FMI), Esperion Therapeutics (ESPR), Arena Pharmaceuticals (ARNA), Crispr Therapeutics (CRSP), Daqo New Energy (DQ), Sorrento Therapeutics (SRNE), Juno Therapeutics (JUNO), Halozyme Therapeutics (HALO), Uniqure (QURE), Mirati Therapeutics (MRTX), Revance Therapeutics (RVNC), Cheetah Mobile (CMCM), Chegg (CHGG), GlycoMimetics (GLYC), and Abeona Therapeutics (ABEO), amongst many more."...

na dann.

VG